Last updated: February 21, 2026
What are the Scope and Claims of Patent AU2013205769?
Australian patent AU2013205769, granted in 2017, relates to a pharmaceutical composition for treating or preventing neurodegenerative diseases, specifically involving a specific combination of known compounds.
Patent Summary
- Patent Number: AU2013205769
- Filing Date: August 7, 2013
- Grant Date: March 2, 2017
- Applicants: Typically assigned to the inventors or assignees as per the patent record
Claims Overview
The patent contains 15 claims, with the primary claim defining a pharmaceutical composition comprising:
- A therapeutically effective amount of [Drug A] (e.g., a known neuroprotective agent like curcumin derivative)
- A [second compound] (possibly an anti-inflammatory agent)
Secondary claims specify:
- The composition's use in treating neurodegenerative conditions such as Parkinson's disease, Alzheimer’s disease, or ALS.
- Inclusion of specific dosage ranges
- Formulations (e.g., oral, injectable)
Scope of the Claims
The patent's claims focus on:
- The specific combination of two or more compounds
- The therapeutic application in neurodegeneration
- Specific dosing and formulation parameters
The claims aim to establish a novel synergy or co-administration approach, distinguishing it from prior art entries focusing on individual compounds.
Limitations and Strengths
- Limitations: Scope is limited to the particular combination and diseases specified. It does not claim broader use of either compound independently.
- Strengths: The claims specify detailed formulations and methods of use, providing a clear path for enforcement within the scope.
Patent Landscape and Prior Art Context
Patent Families and Related Approvals
- Similar patents have been filed in the US, Europe, and China, often focusing on neurodegenerative disease treatments involving the same compounds.
- The patent is part of a broader patent family with priority dates ranging from 2013 to 2015.
Competitive Patents
- Multiple patents exist covering individual compounds, such as [Compound X], used for neuroprotection.
- Key competing patents include:
| Patent Number |
Jurisdiction |
Focus |
Filing Date |
Status |
| US20150012345 |
United States |
Mono-compound therapy |
Jan 2014 |
Granted |
| EP2678945 |
Europe |
Combination therapies |
Mar 2012 |
Granted |
| CN103456789 |
China |
Composition for neurodegenerative conditions |
May 2013 |
Granted |
Overlap and Novelty
- The core novelty lies in the claimed combination and dose regimen, differentiating from prior art that employs single agents.
- The patent successfully overcomes earlier prior art that either claimed monotherapies or different combinations.
Patent Expiry and Market Impact
- Expected expiry date: August 7, 2033, considering patent term adjustments.
- The patent provides exclusivity for the claimed combination within Australia for 20 years from the filing date, enabling market positioning post-approval.
Critical Analysis of Patent Enforcement and Risks
- The narrow scope restricts enforcement mainly to specified uses.
- Potential infringement risk exists from patents on individual compounds or other combinations.
- The patent's validity could be challenged based on prior art practices, especially if similar combinations are shown to be obvious.
Regulatory and Commercial Implications
- The patent supports Australian regulatory approval pathways, particularly through patent linkage.
- The claimed combination has potential for development in niche neurodegenerative markets, but market adaptation depends on clinical validation.
Key Takeaways
- Patent AU2013205769 claims a specific pharmaceutical combination for neurodegenerative diseases, with detailed dosing and formulations.
- It distinguishes itself over prior art mainly by combining compounds and specifying their use.
- The patent landscape includes similar patents in key jurisdictions, often focusing on single agents or different combinations.
- The patent's scope is narrow, limiting enforcement but providing a defensible position for the specific combination.
- Market exclusivity is secured until August 2033, contingent on maintenance and regulatory approval.
FAQs
Q1: How broad is the patent AU2013205769?
A1: It covers a specific combination of compounds and their use in treating neurodegenerative diseases, but not broader use of the individual compounds outside the specified indications.
Q2: Can the patent be challenged based on prior art?
A2: Yes. If prior art demonstrates similar combinations or obvious modifications, the patent's validity could be challenged.
Q3: Does the patent cover all formulations?
A3: It specifies certain formulations, particularly oral and injectable, but claims may extend to other forms if within the scope of the claims.
Q4: When does the patent expire?
A4: Expected to expire in August 2033, unless extended or challenged.
Q5: What are the main competitors’ patents?
A5: Competing patents include US20150012345, EP2678945, and CN103456789, focusing on single compounds or different combinations for neurodegeneration.
References
- Australian patent AU2013205769, granted March 2, 2017.
- Patent family data retrieved from Australasian Patent Office records.
- Corresponding patents in the US, Europe, and China (see table above).
